A REVIEW OF BCR ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASM WITH DENTAL IMPLICATIONS

A REVIEW OF BCR ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASM WITH DENTAL IMPLICATIONS

BCR-ABL1 negative myeloproliferative neoplasms (MPN) primarily include: Essential thrombocythemia (ET), Polycythemia vera (PV), and Primary myelofibrosis (PMF). They are considered rare hematological malignancies. Lately, with ongoing advances in the field of genetics and molecular biology, more cla...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteur:	Madhura Bhatt
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Associazione Italiana Giovani Medici 2022-01-01
Reeks:	Euromediterranean Biomedical Journal
Onderwerpen:	myeloproliferative neoplasm (mpn) polycythemia vera (pv) essential thrombocythemia (et) primary myelofibrosis (pmf) dental implications
Online toegang:	http://www.embj.org/wp-content/uploads/2022/01/Bhatt_04.pdf

Gelijkaardige items

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
door: Steffen Koschmieder
Gepubliceerd in: (2021-06-01)

Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review
door: Abdulrahman F. Al-Mashdali, et al.
Gepubliceerd in: (2023-01-01)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
door: Alessandro Allegra, et al.
Gepubliceerd in: (2020-10-01)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
door: Moysés Antonio Porto-Soares, et al.
Gepubliceerd in: (2020-07-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
door: Sylvie Hermouet, et al.
Gepubliceerd in: (2023-05-01)

Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
door: Christopher Puli'uvea, et al.
Gepubliceerd in: (2024-12-01)

New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
door: Domenico Penna
Gepubliceerd in: (2021-10-01)

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
door: Tarinee Rungjirajittranon, et al.
Gepubliceerd in: (2019-02-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
door: Yoko Edahiro, et al.
Gepubliceerd in: (2024-12-01)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
door: Lucia Catani, et al.
Gepubliceerd in: (2021-09-01)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
door: Aleksandra Mroczkowska-Bękarciak, et al.
Gepubliceerd in: (2023-09-01)

Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms
door: Roelof H. Bekendam, et al.
Gepubliceerd in: (2023-06-01)

Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
door: Mihnea-Alexandru Găman, et al.
Gepubliceerd in: (2023-01-01)

Recent insights regarding the molecular basis of myeloproliferative neoplasms
door: Mi-Ae Jang, et al.
Gepubliceerd in: (2020-01-01)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
door: Jingbo Yu, et al.
Gepubliceerd in: (2018-04-01)

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada
door: Jonathan Heppner, et al.
Gepubliceerd in: (2019-05-01)

NEW APPROACHES TO THERAPY OF CLASSICAL PH-NEGATIVE MYELOPROLIFERATIVE DISEASES: THE EXPERIENCE OF EARLY THERAPY WITH CEPEGINTERFERON ALPHA-2B
door: A. S. Polyakov, et al.
Gepubliceerd in: (2018-05-01)

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study
door: Kasper M. Pedersen, et al.
Gepubliceerd in: (2018-11-01)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
door: Paulo Vidal Campregher, et al.
Gepubliceerd in: (2012-01-01)

The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
door: Sung-Yong Kim, et al.
Gepubliceerd in: (2021-01-01)

Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
door: Mihnea-Alexandru Găman, et al.
Gepubliceerd in: (2021-07-01)

Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review
door: Samuel Bogdan Todor, et al.
Gepubliceerd in: (2024-08-01)

Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm
door: Ik-Chan Song, et al.
Gepubliceerd in: (2021-09-01)

Philadelphia-negative chronic myeloproliferative neoplasms
door: Rosane Isabel Bittencourt, et al.
Gepubliceerd in: (2012-01-01)

MPL W515 L/K mutations in myeloproliferative neoplasms
door: Sohaila Eldeweny, et al.
Gepubliceerd in: (2019-12-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
door: Fadul A, et al.
Gepubliceerd in: (2024-12-01)

Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mieloproliferative Philadelphia- negative
door: Olteanu Ariela Ligia, et al.
Gepubliceerd in: (2016-09-01)

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
door: L. A. Kesaeva, et al.
Gepubliceerd in: (2019-07-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
door: Giuseppe G. Loscocco, et al.
Gepubliceerd in: (2021-08-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
door: Hisashi Ishida, et al.
Gepubliceerd in: (2020-07-01)

CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
door: Liana Gercheva, et al.
Gepubliceerd in: (2014-09-01)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
door: Hans C. Hasselbalch, et al.
Gepubliceerd in: (2020-08-01)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
door: A. Kaifie, et al.
Gepubliceerd in: (2016-03-01)

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm
door: Umi Kalsom Mohamad Yusof, et al.
Gepubliceerd in: (2023-10-01)

Janus kinase inhibitors: jackpot or potluck?
door: Pavithran Keechilat, et al.
Gepubliceerd in: (2012-06-01)

Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective
door: Sarah Kelliher, et al.
Gepubliceerd in: (2021-12-01)

Chronic myeloproliferative disorders: A rarest case with oral manifestations and dental management
door: Pritesh B Ruparelia, et al.
Gepubliceerd in: (2012-01-01)

Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients
door: Cigdem Yuce Kahraman, et al.
Gepubliceerd in: (2022-01-01)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
door: Graeme Greenfield, et al.
Gepubliceerd in: (2018-12-01)

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
door: Marko Lucijanic, et al.
Gepubliceerd in: (2024-04-01)